Selumetinib

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Neurofibromatosis 1

Conditions

Neurofibromatosis 1, Plexiform Neurofibroma (PN)

Trial Timeline

Nov 19, 2021 → Feb 15, 2029

NCT ID

NCT04924608

About Selumetinib

Selumetinib is a phase 3 stage product being developed by AstraZeneca for Neurofibromatosis 1. The current trial status is active. This product is registered under clinical trial identifier NCT04924608. Target conditions include Neurofibromatosis 1, Plexiform Neurofibroma (PN).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03259633	Pre-clinical	Completed	—	—	NF type1 With Inoperable Plexiform Neurofibromas
NCT04924608	Phase 3	Active	Nov 19, 2021	Feb 15, 2029	Neurofibromatosis 1
NCT05101148	Phase 1	Active	Jul 21, 2021	Apr 28, 2028	Neurofibromatosis Type 1
NCT04590235	Phase 1	Active	Dec 16, 2020	Aug 31, 2026	Neurofibromatosis 1
NCT04495127	Phase 1	Completed	Aug 31, 2020	Mar 24, 2023	Neurofibromatosis Type 1
NCT03326388	Phase 1/2	Completed	Sep 26, 2019	Feb 14, 2024	Neurofibromatosis Type 1
NCT03095248	Phase 2	Terminated	May 8, 2017	May 21, 2024	Neurofibromatosis 2
NCT02063204	Phase 1	Completed	Mar 1, 2014	Jul 1, 2014	Solid Tumours
NCT01960374	Phase 1	Completed	Oct 1, 2013	May 1, 2014	Healthy Volunteers Pharmacokinetic Study
NCT01752569	Phase 1/2	Terminated	Jun 15, 2012	Dec 20, 2017	AIDS-related Kaposi's Sarcoma

Competing Products

20 competing products in Neurofibromatosis 1

See all competitors

Product	Company	Stage	Hype Score
Selumetinib	AstraZeneca	Phase 2	27
Selumetinib	AstraZeneca	Phase 1	33
Selumetinib	AstraZeneca	Phase 1	29
AZD2014	AstraZeneca	Phase 2	35
Selumetinib + Placebo	AstraZeneca	Phase 2	27
Treatment A + Treatment B + Treatment C + Treatment D + Acetaminophen	AstraZeneca	Phase 1	29
Selumetinib	AstraZeneca	Phase 1/2	32
Selumetinib	AstraZeneca	Phase 1	33
Selumetinib granule formulation + Selumetinib capsule formulation	AstraZeneca	Phase 1/2	36
Everolimus (RAD001) , Afinitor®	Novartis	Phase 2	35
RAD001: Everolimus	Novartis	Phase 2	35
RAD001, everolimus	Novartis	Phase 2	27
Tasigna	Novartis	Phase 1	29
Trametinib	Novartis	Phase 2	39
Everolimus (RAD001)	Novartis	Phase 2	27
Sutent®/Sunitinib	Pfizer	Phase 2	27
Sorafenib (Nexavar)	Bayer	Phase 2	24
PTC299	United Therapeutics	Phase 2	24
REC-2282 + Placebo	Recursion Pharmaceuticals	Phase 2/3	24
Binimetinib	Pacific Biosciences	Phase 2	25